Andropause Symptoms: What Could Be Causing Them and When to Get Tested

What Andropause Actually Means

Andropause describes the age-related decline in circulating testosterone and bioavailable androgens in men, a process the Endocrine Society formally terms "late-onset hypogonadism" (LOH) [1]. Unlike menopause in women, which occurs over a defined 2-to-5-year window with a clear endpoint, andropause is gradual. Testosterone production decreases at approximately 1-2% per year starting around age 30, according to longitudinal data from the Massachusetts Male Aging Study (MMAS), which followed 1,709 men over nearly two decades [2].

The decline is not uniform. Some men maintain testosterone levels well within the normal range into their 70s. Others drop below the symptomatic threshold by their mid-40s. The European Male Ageing Study (EMAS), which enrolled 3,369 men aged 40-79, found that only 2.1% of community-dwelling men met strict criteria for LOH when both biochemical and symptomatic standards were applied [3]. That figure rose to 5.1% among men aged 70-79. The gap between biochemical hypogonadism (low numbers on a lab slip) and clinical hypogonadism (low numbers plus symptoms that impair quality of life) is the central challenge of andropause diagnosis.

The hypothalamic-pituitary-gonadal (HPG) axis undergoes two concurrent changes with aging. Leydig cells in the testes produce less testosterone in response to luteinizing hormone (LH), and the hypothalamus becomes less responsive to low-testosterone feedback signals [1]. Sex hormone-binding globulin (SHBG) also increases with age, binding more circulating testosterone and reducing the bioavailable fraction. A man whose total testosterone reads 350 ng/dL but whose SHBG is elevated may have a free testosterone level equivalent to someone with a total of 250 ng/dL.

Core Symptoms and How They Cluster

The most reliable andropause symptoms fall into three categories: sexual, physical, and psychological. The EMAS data identified only three symptoms with a syndromic association to low testosterone levels: poor morning erections, low sexual desire, and erectile dysfunction [3]. These sexual symptoms showed the strongest and most specific correlation with biochemical testosterone decline.

Physical symptoms include reduced muscle mass, increased visceral fat, decreased bone mineral density, and persistent fatigue. A 2010 analysis in the New England Journal of Medicine demonstrated that body composition changes (increased body fat, decreased lean mass) began appearing at testosterone levels below approximately 300 ng/dL, while sexual symptoms emerged below roughly 230 ng/dL [4]. This staggered threshold means a man can notice physical changes before sexual dysfunction appears.

Psychological symptoms are real but harder to attribute. Irritability, difficulty concentrating, depressed mood, and reduced motivation overlap heavily with primary mood disorders. The Testosterone Trials (TTrials), a coordinated set of seven randomized controlled trials enrolling 790 men aged 65 and older with testosterone below 275 ng/dL, found that testosterone gel modestly improved sexual function and walking distance but produced only minor improvements in mood and vitality [5]. That modest mood effect is important context: if mood symptoms are severe, testosterone therapy alone may not resolve them.

Causes Beyond Normal Aging

Not all symptoms attributed to andropause are caused by testosterone decline. Several conditions produce identical symptom profiles and may coexist with or accelerate androgen loss.

Obstructive sleep apnea (OSA) suppresses nocturnal testosterone production and causes daytime fatigue, cognitive fog, and reduced libido. A study published in the Journal of Clinical Endocrinology & Metabolism found that men with severe OSA had total testosterone levels approximately 60 ng/dL lower than matched controls without OSA [6]. Treating OSA with CPAP can partially restore testosterone levels without hormone therapy.

Type 2 diabetes and metabolic syndrome are strongly linked to low testosterone. The Endocrine Society's 2018 guideline notes that approximately 30-50% of men with type 2 diabetes have testosterone levels below 300 ng/dL [1]. The relationship runs in both directions: low testosterone promotes insulin resistance, and hyperinsulinemia suppresses gonadotropin release. Weight loss of 5-10% body weight can increase testosterone by 50-100 ng/dL in obese men, according to data from a meta-analysis of lifestyle intervention trials [7].

Hypothyroidism mimics andropause through fatigue, weight gain, depressed mood, cold intolerance, and reduced libido. A simple TSH and free T4 panel rules it out. Chronic opioid use is an increasingly recognized cause of symptomatic hypogonadism. Opioids suppress GnRH release from the hypothalamus, and testosterone suppression occurs in roughly 50-85% of men on long-term opioid therapy [8]. Hyperprolactinemia, often from a pituitary microadenoma, produces a similar picture of low libido and erectile dysfunction and requires a serum prolactin level for diagnosis.

Depression deserves its own mention. The symptom overlap between major depressive disorder and andropause is nearly complete: low energy, poor concentration, sleep disruption, reduced interest in sex, weight changes, irritability. The PHQ-9 screening tool, combined with testosterone levels, helps parse the two. In some men, both conditions are present simultaneously, and treating only one leaves the other untreated.

The Diagnostic Workup

The Endocrine Society's 2018 clinical practice guideline recommends measuring total testosterone by a reliable assay (liquid chromatography-tandem mass spectrometry, or LC-MS/MS) on two separate mornings before 10:00 AM, since testosterone follows a circadian rhythm with peak levels in the early morning [1]. A total testosterone below 300 ng/dL (10.4 nmol/L) on both draws, paired with consistent symptoms, confirms the diagnosis.

If total testosterone falls between 200 and 400 ng/dL, measuring free testosterone or bioavailable testosterone helps clarify the clinical picture, especially in men with conditions that alter SHBG (obesity lowers SHBG; aging and liver disease raise it). Calculated free testosterone below 6.5 ng/dL is generally considered low.

Additional labs in the initial workup should include LH and FSH (to distinguish primary from secondary hypogonadism), prolactin, TSH, a comprehensive metabolic panel, hemoglobin A1c, and a complete blood count. An elevated LH with low testosterone points to primary testicular failure. A low or inappropriately normal LH with low testosterone suggests a hypothalamic or pituitary cause, which may warrant pituitary MRI, particularly if prolactin is elevated or testosterone is below 150 ng/dL.

The American Urological Association (AUA) issued a parallel guideline in 2018 using the same 300 ng/dL threshold while emphasizing that symptoms must be present and bothersome before initiating therapy [9]. Both guidelines explicitly recommend against mass screening in asymptomatic men.

Lifestyle Interventions That Move the Needle

Before starting testosterone therapy, or alongside it, lifestyle modifications can meaningfully affect hormone levels and symptom burden. These are not placebo-grade suggestions. The evidence supports quantifiable changes.

Resistance training increases acute testosterone release and, over 12-16 weeks of consistent training, can raise baseline testosterone by 15-20% in previously sedentary men. A meta-analysis published in Sports Medicine found that resistance exercise produced the most reliable testosterone response compared to endurance exercise, which can actually suppress testosterone when performed at high volume [10].

Weight loss is the single most effective non-pharmacological intervention for obese men with low testosterone. The MMAS data showed that a 4-5 point increase in BMI produced a testosterone decline equivalent to 10 years of aging [2]. Bariatric surgery studies demonstrate testosterone increases of 200-300 ng/dL following significant weight loss in morbidly obese men, frequently normalizing levels entirely [7].

Sleep optimization matters because 65-70% of daily testosterone secretion occurs during sleep. A University of Chicago study restricted young healthy men to five hours of sleep for one week and measured a 10-15% decrease in daytime testosterone, equivalent to adding 10-15 years of aging [11]. Men reporting andropause symptoms should be screened for sleep disorders and counseled on sleep duration (7-9 hours) as a first-line intervention.

Alcohol reduction has a dose-dependent relationship with testosterone. Moderate intake (1-2 drinks per day) shows minimal impact, but chronic heavy drinking directly damages Leydig cells and increases aromatase-mediated conversion of testosterone to estradiol [12].

Testosterone Replacement Therapy: What the Evidence Shows

For men with confirmed hypogonadism (total testosterone below 300 ng/dL on two morning draws, plus symptoms), TRT is an evidence-based treatment option. The TTrials provided the most rigorous efficacy data to date in older men [5]. Among 790 men aged 65 and older randomized to testosterone gel or placebo for 12 months:

Sexual function improved significantly (IIEF score increase of 2.64 points vs. placebo). Walking distance increased modestly (6-minute walk test improved by 6.1 meters). Bone mineral density improved at the spine and hip by 7.5% in the spine. Mood and vitality showed small, statistically significant improvements that did not meet predefined thresholds for clinical significance.

The TRAVERSE trial, published in 2023 in the New England Journal of Medicine, enrolled 5,246 men aged 45-80 with hypogonadism and established or high risk for cardiovascular disease [13]. Over a mean follow-up of 33 months, testosterone replacement did not increase the incidence of major adverse cardiovascular events compared to placebo (hazard ratio 0.96, 95% CI 0.78-1.17). This trial effectively resolved years of concern about cardiovascular safety, leading the FDA to remove its 2015 cardiovascular warning label requirement for testosterone products.

TRT delivery options include topical gels (1-2% testosterone applied daily), intramuscular injections (testosterone cypionate or enanthate, typically 100-200 mg every 1-2 weeks), subcutaneous pellets (implanted every 3-6 months), and nasal gels. Each has trade-offs. Injections produce peak-and-trough fluctuations that some men notice. Gels provide steadier levels but carry a risk of transference to close contacts. Pellets offer convenience but cannot be easily removed if side effects occur.

Monitoring during TRT should include testosterone levels, hematocrit (TRT increases erythropoiesis, and hematocrit above 54% warrants dose reduction or therapeutic phlebotomy), PSA, and a lipid panel at 3, 6, and 12 months, then annually [1]. TRT is contraindicated in men actively trying to conceive, as exogenous testosterone suppresses spermatogenesis, and in men with untreated severe obstructive sleep apnea, polycythemia (hematocrit above 50% at baseline), or active hormone-sensitive cancer.

Non-Testosterone Pharmacological Options

Not every man with andropause symptoms needs or wants exogenous testosterone. Several alternative pharmacological approaches exist for specific symptom clusters.

Clomiphene citrate (25-50 mg daily, used off-label) stimulates LH and FSH release from the pituitary, increasing endogenous testosterone production while preserving fertility. A retrospective study of 86 hypogonadal men treated with clomiphene showed a mean testosterone increase from 228 ng/dL to 612 ng/dL over 12 months [14]. Clomiphene is a particularly useful option for younger men who want symptom relief without sacrificing spermatogenesis.

Anastrozole (1 mg two to three times weekly, off-label) blocks aromatase, reducing estradiol and increasing testosterone through feedback disinhibition. It works best in obese men with elevated estradiol levels. The Endocrine Society does not formally recommend aromatase inhibitors for hypogonadism due to concerns about bone density with long-term estrogen suppression [1].

PDE5 inhibitors (sildenafil, tadalafil) directly address erectile dysfunction regardless of testosterone status. For men whose primary complaint is ED, a PDE5 inhibitor trial is reasonable before or alongside testosterone evaluation, especially if testosterone is in the borderline range (250-350 ng/dL).

Enclomiphene, the trans-isomer of clomiphene, received FDA attention for its more targeted action on the HPG axis with fewer estrogenic side effects than racemic clomiphene. While not yet FDA-approved as a standalone product for hypogonadism, it represents a potential future option for men seeking to raise endogenous testosterone [15].

When Symptoms Demand Urgent Evaluation

Most andropause symptoms develop over months to years. Rapid onset should prompt a different diagnostic approach. If a man under 50 develops sudden-onset severe fatigue, complete loss of libido, and erectile dysfunction over weeks rather than months, the differential includes pituitary apoplexy, pituitary adenoma, infiltrative diseases (hemochromatosis, sarcoidosis), or anabolic steroid withdrawal.

Visual field changes (bitemporal hemianopia) combined with low testosterone and low LH require urgent pituitary MRI. Serum ferritin above 300 ng/mL with low testosterone should prompt evaluation for hereditary hemochromatosis, which deposits iron in the pituitary and gonads. Testicular pain, swelling, or a palpable mass with low testosterone warrants testicular ultrasound to exclude malignancy.

Men with osteoporotic fractures and low testosterone should be evaluated for additional secondary causes. The 2020 Endocrine Society guideline on male osteoporosis recommends dual-energy X-ray absorptiometry (DEXA) screening for men over 70 universally and for men aged 50-69 with risk factors including confirmed hypogonadism [16].

Tracking Symptom Response After Treatment

Quantifying treatment response requires baseline measurements. The Aging Males' Symptoms (AMS) scale and the quantitative Androgen Deficiency in the Aging Male (qADAM) questionnaire are validated tools for tracking symptom severity over time [17]. Sexual symptoms typically respond within 3-6 weeks of achieving therapeutic testosterone levels. Body composition changes (increased lean mass, decreased fat mass) require 12-16 weeks. Bone density improvements take 6-12 months and are best measured by follow-up DEXA scan.

If symptoms fail to improve after 3-6 months of therapy with documented therapeutic testosterone levels (target: 450-600 ng/dL mid-cycle), the diagnosis should be reconsidered. Persistent fatigue despite normalized testosterone may indicate untreated sleep apnea, depression, or thyroid dysfunction. Persistent ED may reflect vascular disease that requires independent evaluation with duplex Doppler ultrasound of the penile arteries.

A reasonable first re-evaluation is at 90 days. Check total testosterone (trough level for injections, steady-state level for gels), free testosterone, hematocrit, estradiol, and PSA. Adjust the dose to maintain total testosterone between 450 and 700 ng/dL, and reduce or hold therapy if hematocrit exceeds 54%.